Trans-scleral delivery of antiangiogenic proteins

Anna M. Demetriades, Tye Deering, Hansheng Liu, Lili Lu, Peter Gehlbach, Jonathan D. Packer, Feilim Mac Gabhann, Aleksander S Popel, Lisa L. Wei, Peter A Campochiaro

Research output: Contribution to journalArticle

Abstract

Purpose: In this study, we investigated the penetration of various proteins into the mouse eye after a periocular injection of the protein or an adenoviral vector (Ad) expressing the protein. Methods: At several time points after the injection, the retina, retinal pigmented epithelium/choroid, and sclera were dissected and enzyme-linked immunosorbent assays were performed. Results: After a periocular injection of AdsFlt-1.10, AdTGFβ.10, or AdPEDF.11, choroidal levels of pigment epithelium-derived factor (PEDF) and transforming growth factor-β (TGF-β) were not significantly different from scleral levels, and choroidal levels of sFlt-1 (soluble Flt-1 or soluble VEGF receptor 1) were only moderately reduced from scleral levels, indicating that each of these proteins penetrate the sclera well. In contrast, retinal levels of each of the three proteins were low compared to choroidal levels, suggesting poor penetration into the retina. Levels of PEDF in the choroid peaked 2 h after a periocular injection of PEDF protein and returned to baseline between 6 and 24 h, and peak levels in the retina were 8.6% of peak choroidal levels. Levels of green fluorescent protein, a protein unlikely to have any binding sites in mouse tissues, peaked in the choroid 2 h after the periocular injection and were undetectable by 4 h, while peak levels in the retina were 64.3% of peak choroidal levels. Conclusions: These data suggest that size and binding characteristics of proteins are likely to influence their ability to penetrate the eye from the periocular space, but in general, proteins as large as 50-75 kDa penetrate well into the choroid, but not into the retina. Periocular injections are feasible for the treatment of choroidal neovascularization with proteins or vectors that express them, but additional investigations are needed before they can be considered for treatment of retinal diseases.

Original languageEnglish (US)
Pages (from-to)70-79
Number of pages10
JournalJournal of Ocular Pharmacology and Therapeutics
Volume24
Issue number1
DOIs
StatePublished - Feb 1 2008

Fingerprint

Intraocular Injections
Choroid
Retina
Proteins
Sclera
Retinal Diseases
Choroidal Neovascularization
Vascular Endothelial Growth Factor Receptor
Transforming Growth Factors
Green Fluorescent Proteins
Carrier Proteins
Epithelium
Enzyme-Linked Immunosorbent Assay
Binding Sites
Injections
Therapeutics
pigment epithelium-derived factor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Ophthalmology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Trans-scleral delivery of antiangiogenic proteins. / Demetriades, Anna M.; Deering, Tye; Liu, Hansheng; Lu, Lili; Gehlbach, Peter; Packer, Jonathan D.; Gabhann, Feilim Mac; Popel, Aleksander S; Wei, Lisa L.; Campochiaro, Peter A.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 24, No. 1, 01.02.2008, p. 70-79.

Research output: Contribution to journalArticle

Demetriades, Anna M. ; Deering, Tye ; Liu, Hansheng ; Lu, Lili ; Gehlbach, Peter ; Packer, Jonathan D. ; Gabhann, Feilim Mac ; Popel, Aleksander S ; Wei, Lisa L. ; Campochiaro, Peter A. / Trans-scleral delivery of antiangiogenic proteins. In: Journal of Ocular Pharmacology and Therapeutics. 2008 ; Vol. 24, No. 1. pp. 70-79.
@article{da71c0df8b544387890407de7366411f,
title = "Trans-scleral delivery of antiangiogenic proteins",
abstract = "Purpose: In this study, we investigated the penetration of various proteins into the mouse eye after a periocular injection of the protein or an adenoviral vector (Ad) expressing the protein. Methods: At several time points after the injection, the retina, retinal pigmented epithelium/choroid, and sclera were dissected and enzyme-linked immunosorbent assays were performed. Results: After a periocular injection of AdsFlt-1.10, AdTGFβ.10, or AdPEDF.11, choroidal levels of pigment epithelium-derived factor (PEDF) and transforming growth factor-β (TGF-β) were not significantly different from scleral levels, and choroidal levels of sFlt-1 (soluble Flt-1 or soluble VEGF receptor 1) were only moderately reduced from scleral levels, indicating that each of these proteins penetrate the sclera well. In contrast, retinal levels of each of the three proteins were low compared to choroidal levels, suggesting poor penetration into the retina. Levels of PEDF in the choroid peaked 2 h after a periocular injection of PEDF protein and returned to baseline between 6 and 24 h, and peak levels in the retina were 8.6{\%} of peak choroidal levels. Levels of green fluorescent protein, a protein unlikely to have any binding sites in mouse tissues, peaked in the choroid 2 h after the periocular injection and were undetectable by 4 h, while peak levels in the retina were 64.3{\%} of peak choroidal levels. Conclusions: These data suggest that size and binding characteristics of proteins are likely to influence their ability to penetrate the eye from the periocular space, but in general, proteins as large as 50-75 kDa penetrate well into the choroid, but not into the retina. Periocular injections are feasible for the treatment of choroidal neovascularization with proteins or vectors that express them, but additional investigations are needed before they can be considered for treatment of retinal diseases.",
author = "Demetriades, {Anna M.} and Tye Deering and Hansheng Liu and Lili Lu and Peter Gehlbach and Packer, {Jonathan D.} and Gabhann, {Feilim Mac} and Popel, {Aleksander S} and Wei, {Lisa L.} and Campochiaro, {Peter A}",
year = "2008",
month = "2",
day = "1",
doi = "10.1089/jop.2007.0061",
language = "English (US)",
volume = "24",
pages = "70--79",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Trans-scleral delivery of antiangiogenic proteins

AU - Demetriades, Anna M.

AU - Deering, Tye

AU - Liu, Hansheng

AU - Lu, Lili

AU - Gehlbach, Peter

AU - Packer, Jonathan D.

AU - Gabhann, Feilim Mac

AU - Popel, Aleksander S

AU - Wei, Lisa L.

AU - Campochiaro, Peter A

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Purpose: In this study, we investigated the penetration of various proteins into the mouse eye after a periocular injection of the protein or an adenoviral vector (Ad) expressing the protein. Methods: At several time points after the injection, the retina, retinal pigmented epithelium/choroid, and sclera were dissected and enzyme-linked immunosorbent assays were performed. Results: After a periocular injection of AdsFlt-1.10, AdTGFβ.10, or AdPEDF.11, choroidal levels of pigment epithelium-derived factor (PEDF) and transforming growth factor-β (TGF-β) were not significantly different from scleral levels, and choroidal levels of sFlt-1 (soluble Flt-1 or soluble VEGF receptor 1) were only moderately reduced from scleral levels, indicating that each of these proteins penetrate the sclera well. In contrast, retinal levels of each of the three proteins were low compared to choroidal levels, suggesting poor penetration into the retina. Levels of PEDF in the choroid peaked 2 h after a periocular injection of PEDF protein and returned to baseline between 6 and 24 h, and peak levels in the retina were 8.6% of peak choroidal levels. Levels of green fluorescent protein, a protein unlikely to have any binding sites in mouse tissues, peaked in the choroid 2 h after the periocular injection and were undetectable by 4 h, while peak levels in the retina were 64.3% of peak choroidal levels. Conclusions: These data suggest that size and binding characteristics of proteins are likely to influence their ability to penetrate the eye from the periocular space, but in general, proteins as large as 50-75 kDa penetrate well into the choroid, but not into the retina. Periocular injections are feasible for the treatment of choroidal neovascularization with proteins or vectors that express them, but additional investigations are needed before they can be considered for treatment of retinal diseases.

AB - Purpose: In this study, we investigated the penetration of various proteins into the mouse eye after a periocular injection of the protein or an adenoviral vector (Ad) expressing the protein. Methods: At several time points after the injection, the retina, retinal pigmented epithelium/choroid, and sclera were dissected and enzyme-linked immunosorbent assays were performed. Results: After a periocular injection of AdsFlt-1.10, AdTGFβ.10, or AdPEDF.11, choroidal levels of pigment epithelium-derived factor (PEDF) and transforming growth factor-β (TGF-β) were not significantly different from scleral levels, and choroidal levels of sFlt-1 (soluble Flt-1 or soluble VEGF receptor 1) were only moderately reduced from scleral levels, indicating that each of these proteins penetrate the sclera well. In contrast, retinal levels of each of the three proteins were low compared to choroidal levels, suggesting poor penetration into the retina. Levels of PEDF in the choroid peaked 2 h after a periocular injection of PEDF protein and returned to baseline between 6 and 24 h, and peak levels in the retina were 8.6% of peak choroidal levels. Levels of green fluorescent protein, a protein unlikely to have any binding sites in mouse tissues, peaked in the choroid 2 h after the periocular injection and were undetectable by 4 h, while peak levels in the retina were 64.3% of peak choroidal levels. Conclusions: These data suggest that size and binding characteristics of proteins are likely to influence their ability to penetrate the eye from the periocular space, but in general, proteins as large as 50-75 kDa penetrate well into the choroid, but not into the retina. Periocular injections are feasible for the treatment of choroidal neovascularization with proteins or vectors that express them, but additional investigations are needed before they can be considered for treatment of retinal diseases.

UR - http://www.scopus.com/inward/record.url?scp=38549113408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549113408&partnerID=8YFLogxK

U2 - 10.1089/jop.2007.0061

DO - 10.1089/jop.2007.0061

M3 - Article

VL - 24

SP - 70

EP - 79

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 1

ER -